Advertisement

Targeted Ablative Therapies for Prostate Cancer

  • Jared S. Winoker
  • Harry Anastos
  • Ardeshir R. Rastinehad
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 175)

Abstract

Men diagnosed with low- to intermediate-risk, clinically localized prostate cancer (PCa) often face a daunting and difficult decision with respect to treatment: active surveillance (AS) or radical therapy. This decision is further confounded by the fact that many of these men diagnosed, by an elevated PSA, will have indolent disease and never require intervention. Radical treatments, including radical prostatectomy and whole-gland radiation, offer greater certainty for cancer control, but at the risk of significant urinary and/or sexual morbidity. Conversely, AS preserves genitourinary function and quality of life in exchange for burdensome surveillance and the psychological impact of living with cancer.

Keywords

Focal therapy Prostate cancer treatment Biochemical recurrence High-intensity focused ultrasound Radiofrequency ablation Photodynamic therapy Electroporation 

References

  1. 1.
    Potosky AL et al (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96:1358–1367PubMedCrossRefGoogle Scholar
  2. 2.
    Penson DF, Litwin MS (2003) The physical burden of prostate cancer. Urol Clin North Am 30:305–313PubMedCrossRefGoogle Scholar
  3. 3.
    Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165–8169PubMedCrossRefGoogle Scholar
  4. 4.
    Hardie C et al (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95:956–960PubMedCrossRefGoogle Scholar
  5. 5.
    Womble PR, Montie JE, Ye Z et al (2015) Michigan Urological Surgery Improvement Collaborative. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67(1):44–50PubMedCrossRefGoogle Scholar
  6. 6.
    Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314(1):80–82PubMedCrossRefGoogle Scholar
  7. 7.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRefGoogle Scholar
  8. 8.
    Berglund RK, Masterson TA, Vora KC et al (2008) Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180:1964–1968PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Marshall S, Taneja S (2015) Focal therapy for prostate cancer: the current status. Prostate Int 3(2):35–41PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Felker ER, Margolis DJ, Nassiri N, Marks LS (2016) Prostate cancer risk stratification with magnetic resonance imaging. Urol Oncol 34:311–319PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for diagnosis of prostate cancer. JAMA 313:390PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Rastinehad AR, Turkbey B, Salami SS et al (2014) Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol 191:1749PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60(2):264–269PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Nevoux P, Ouzzane A, Ahmed HU et al (2012) Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int 110(4):517–523PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Liu W, Laitinen S, Khan S et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15(5):559–565PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Villers A, McNeal JE, Freiha FS, Stamey TA (1992) Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 70:2313–2318PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Stamey TA, McNeal JM, Wise AM, Clayton JL. Secondary cancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy. Eur Urol 39(Suppl. 4):22–23 (2001). (or Eur Urol 2001;39:Suppl 4:22–23)Google Scholar
  18. 18.
    Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361(17):1704–1706PubMedCrossRefGoogle Scholar
  19. 19.
    Karavitakis M, Winkler M, Abel P et al (2011) Histological characteristics of the index lesion in whole-mount radical prostatectomy specimen: implications for focal therapy. Prostate Cancer Prostatic Dis 14(1):46–52PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Ahmed HU, Berge V, Bottomley D et al (2014) Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol 11(8):482–491PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Donaldson IA, Alonzi R, Barratt D et al (2015) Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur Urol 67(4):771–777PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Cooper SM, Dawber RPR (2001) The history of cryosurgery. J R Soc Med 94(4):196–201PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Cooper IS (1963) Cryogenic surgery. A new method of destruction or extirpation of benign or malignant tissues. N Engl J Med 263:741–749Google Scholar
  24. 24.
    Bahn DK, Lee F, Badalament R et al (2002) Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(suppl 2A):3–11PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Gonder MJ, Soanes WA, Shulman S (1966) Cryosurgical treatment of the prostate. Invest Urol 3(4):372–378PubMedPubMedCentralGoogle Scholar
  26. 26.
    Soanes WA, Gonder MJ (1968) Use of cryosurgery in prostatic cancer. J Urol 99(6):793–797PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Megalli MR, Gursel EO, Veenema RJ (1974) Closed perineal cryosurgery in prostatic cancer. New Probe Technique. Urol 4(2):220–222PubMedPubMedCentralGoogle Scholar
  28. 28.
    Lee F, Bahn DK, Badalament RA et al (1999) Cryosurgery for prostate cancer: improved ablation by use of 6–8 cryoprobes. Urology 54:135PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J (1993) Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72(4):1291–1299PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ouzzane A, Betrouni N, Valerio M et al (2017) Focal therapy as primary treatment for localized prostate cancer: definition, needs, and future. Future Oncol 13(8):727–741PubMedCrossRefGoogle Scholar
  31. 31.
    Mohammad A, Miller S, Douglas-Moore J et al (2014) Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers. Urol Oncol 32:39Google Scholar
  32. 32.
    Hoffman NE, Bischof JC (2002) The cryobiology of cryosurgical injury. Urol suppl 60:40CrossRefGoogle Scholar
  33. 33.
    Sprenkle PC, Mirabile G, Durak E et al (2010) The effect of argon gas pressure on ice ball size and rate of formation. J Endourol 24(9):1503–1507PubMedCrossRefGoogle Scholar
  34. 34.
    De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA et al (2000) Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 85(3):281–286CrossRefGoogle Scholar
  35. 35.
    Lambert EH, Bolte K, Masson P, Katz AE (2007) Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urol 69:1117–1120PubMedCrossRefGoogle Scholar
  36. 36.
    Truesdale MD, Cheetham PJ, Hruby GW (2010) An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J 16:544–549PubMedCrossRefGoogle Scholar
  37. 37.
    Ward JF, Jones JS (2012) Focal cryotherapy for localized prostate cancer: a report from the national cryo on-line database (COLD) registry. BJUI 109(11):1648–1654CrossRefGoogle Scholar
  38. 38.
    Onik G, Vaughan D, Lotenfoe R et al (2008) The male lumpectomy: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 26:500–505PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Cordeiro ER, Cathelineau X, Thuroff S et al (2012) High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJUI 110(9):1228–1242CrossRefGoogle Scholar
  40. 40.
    Lynn JG, Zwemer RL, Chick AJ, Miller AE (1942) A new method for the generation and use of focused ultrasound in experimental biology. J Gen Physiol 26:179–192PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Fry WJ, Fry FJ (1960) Fundamental neurological research and human neurosurgery using intense ultrasound. IRE Trans Biomed Electron ME-7:166–181Google Scholar
  42. 42.
    Fry FJ, Johnson LK (1978) Tumour irradiation with intense ultrasound. Ultrasound Med Biol 4:337–341PubMedCrossRefGoogle Scholar
  43. 43.
    Rosenberg RS, Purnell E (1967) Effects of ultrasonic radiation on the ciliary body. Am J Ophthalmol 63:403–409PubMedCrossRefGoogle Scholar
  44. 44.
    Coleman DJ, Lizzi FL, Driller J, Rosado AL, Burgess SEP, Torpey JH, Smith ME, Silverman RH, Yablonski ME, Chang S et al (1985) Therapeutic ultrasound in the treatment of glaucoma—II clinical applications. Ophthalmol 92:347–353CrossRefGoogle Scholar
  45. 45.
    Madersbacher S, Kratzik C, Susani M, Marberger M (1994) Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 152:1956–1960PubMedCrossRefGoogle Scholar
  46. 46.
    Gelet A, Chapelon JY, Margonari J et al (1993) High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol 23(Suppl. 1):44–47PubMedCrossRefGoogle Scholar
  47. 47.
    Hegarty NJ, Fitzpatrick JM (1999) High intensity focused ultrasound in benign prostatic hyperplasia. Eur J Ultrasound 9:55–60PubMedCrossRefGoogle Scholar
  48. 48.
    Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A (1992) In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 52:6353–6357PubMedGoogle Scholar
  49. 49.
    Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M (1995) Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 55:3346–3351PubMedGoogle Scholar
  50. 50.
    Nelson R FDA approves first HIFU device for prostate tissue ablation. http://www.medscape.com/viewarticle/853120. [Accessed 2 March 2017]
  51. 51.
    Colombel M, Gelet A (2004) Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 7:289–294PubMedCrossRefGoogle Scholar
  52. 52.
    Cordeiro ER, Cathelineau X, Thüroff S et al (2012) High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int 110(9):1228–1242PubMedCrossRefGoogle Scholar
  53. 53.
    Dickinson L et al (2013) Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. BJU Int 112:594–601PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Mearini L, Porena M (2010) Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future. Indian J Urol 26(1):4–11PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Muto S, Yoshii T, Saito K et al (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38(3):192–199PubMedCrossRefGoogle Scholar
  56. 56.
    El Feguon AB, Barret E, Prapotnich D et al (2011) Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 year follow-up. Int Braz J Urol 37(2):213–219CrossRefGoogle Scholar
  57. 57.
    Ahmed HU, Freeman A, Kirkham A (2011) Focal therapy for localised prostate cancer: a phase I/II trial. J Urol 185:1246–1254PubMedCrossRefGoogle Scholar
  58. 58.
    Ahmed HU, Dickinson L, Charman S et al (2015) Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 68:927–936PubMedCrossRefGoogle Scholar
  59. 59.
    Bown SG (1983) Phototherapy in tumors. World J Surg 7:700–709PubMedCrossRefGoogle Scholar
  60. 60.
    Vogl TJ, Straub R, Eichler K et al (2004) Colorectal carcinoma metastases in liver: Laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology 230:450–458PubMedCrossRefGoogle Scholar
  61. 61.
    Pacella CM, Francica G, Di Lascio FM et al (2009) Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol 27:2615–2621PubMedCrossRefGoogle Scholar
  62. 62.
    Sander S, Beisland HO (1984) Laser in the treatment of localized prostatic carcinoma. J Urol 132(2):280–281PubMedCrossRefGoogle Scholar
  63. 63.
    Amin Z, Lees WR, Bown SG (1993) Technical note: interstitial laser photocoagulation for the treatment of prostatic cancer. Br J Radiol 66:1044–1047 PubMedCrossRefGoogle Scholar
  64. 64.
    Johnson DE, Cromeens DM, Price RE (1994) Interstitial laser prostatectomy. Lasers Surg Med 14:299–305PubMedCrossRefGoogle Scholar
  65. 65.
    Atri M, Gertner MR, Haider MA, Weersink RA, Trachtenberg J (2009) Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J 3(2):125–130PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Bomers JGR, Sedelaar JPM, Barentsz JO, Fütterer JJ (2012) MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol 199(4):714–720PubMedCrossRefGoogle Scholar
  67. 67.
    Heisterkamp J, van Hillegersberg R, Ijzermans JN (1999) Critical temperature and heating time for coagulation damage: implications for interstitial laser coagulation (ILC) of tumors. Lasers Surg Med 25:257–262PubMedCrossRefGoogle Scholar
  68. 68.
    Germer CT, Roggan A, Ritz JP et al (1998) Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range. Lasers Surg Med 23:194–203PubMedCrossRefGoogle Scholar
  69. 69.
    Lindner U, Lawrentschuk N, Trachtenberg J (2010) Focal laser ablation for localized prostate cancer. J Endourol 24:791–797PubMedCrossRefGoogle Scholar
  70. 70.
    Colin P, Mordon S, Nevoux P et al (2012) Focal laser ablation of prostate cancer: definition, needs, and future. Adv UrolGoogle Scholar
  71. 71.
    Raz O, Haider MA, Davidson SRH et al (2010) Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 58(1):173–177PubMedCrossRefGoogle Scholar
  72. 72.
    Marqa M-F, Colin P, Nevoux P et al (2011) Focal laser ablation of prostate cancer: numerical simulation of temperature and damage distribution. Biomed Eng Online 10:45PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Lee T, Mendhiratta N, Sperling D et al (2014) Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol 16(2):55–66PubMedPubMedCentralGoogle Scholar
  74. 74.
    Stafford RJ, Shetty A, Elliott AM et al (2010) Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol 184:1514–1520PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Peters RD, Chan E, Trachtenberg J et al (2000) Magnetic resonance thermometry for predicting thermal damage: an application of interstitial laser coagulation in an in vivo canine prostate model. Magn Reson Med 44(6):873–883PubMedCrossRefGoogle Scholar
  76. 76.
    Colin P, Nevoux P, Marqa M et al (2012) Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: treatment feasibility in dunning R3327-AT2 rat prostate tumour. BJU Int 109(3):452–458PubMedCrossRefGoogle Scholar
  77. 77.
    Lindner U, Weersink RA, Haider MA et al (2009) Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 182:1371–1377PubMedCrossRefGoogle Scholar
  78. 78.
    Lindner U, Lawrentschuk N, Weersink RA et al (2010) Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 57:1111–1114PubMedCrossRefGoogle Scholar
  79. 79.
    Raz O, Haider MA, Davidson ST et al (2010) Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 58:173–177PubMedCrossRefGoogle Scholar
  80. 80.
    Oto A, Sethi I, Karczmar G et al (2013) MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 267(3):932–940PubMedCrossRefGoogle Scholar
  81. 81.
    Donadon M, Solbiati L, Dawson L et al (2016) Hepatocellular carcinoma: the role of interventional oncology. Liver Cancer 6(1):34–43PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Song TJ, Seo DW, Lakhtakia S, et al (2016) Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc 83(2):440–443Google Scholar
  83. 83.
    Chen J, Zhang C, Li F et al (2016) A meta-analysis of clinical trials assessing the effect of radiofrequency ablation for breast cancer. Onco Targets Ther 9:1759–1766PubMedPubMedCentralGoogle Scholar
  84. 84.
    Haghjoo M, Arya A, Emkanjoo Z et al (2004) Radiofrequency catheter ablation of idiopathic left ventricular tachycardia originating in both left posterior and anterior fascicles. J Interv Card Electrophysiol 11(3):217–220PubMedCrossRefGoogle Scholar
  85. 85.
    D’Arsonval MA (1891) Action physiologique des courants alternatifs. C R Soc Biol 43:283–286Google Scholar
  86. 86.
    Beer E (1910) Removal of neoplasms of the urinary bladder: a new method employing high frequency (oudin) currents through a cauterizing cystoscope. JAMA 54:1768–1769CrossRefGoogle Scholar
  87. 87.
    Cushing H, Bovie WT (1928) Electro-surgery as an aid to the removal of intracranial tumors. Surg Gynecol Obstet 47:751–784Google Scholar
  88. 88.
    McGahan JP, Browing PD, Brock JM, Tesluk H (1990) Hepatic ablation using radiofrequency electrocautery. Invest Radiol 25:267–270PubMedCrossRefGoogle Scholar
  89. 89.
    Rossi S, Fornari F, Pathies C, Buscarini L (1990) Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. Tumori 76:54–57PubMedCrossRefGoogle Scholar
  90. 90.
    McGahan JP, Brock JM, Tesluk H et al (1992) Hepatic ablation with use of radiofrequency electro-cautery in the animal model. J Vasc Intervent Radiol 3:291–297CrossRefGoogle Scholar
  91. 91.
    Schulman CC, Zlotta AR, Rasor J et al (1993) Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 24:415–423PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Chen YY, Hossack T, Woo H (2011) Long-term results of bipolar radiofrequency needle ablation of the prostate for lower urinary tract symptoms. J Endourol 25(5):837–840PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Zlotta AR, Djavan B, Matos C et al (1998) Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 81:265–275PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Corwin TS, Lindberg G, Traxer O et al (2001) Laparoscopic radiofrequency thermal ablation of renal tissue with and without hilar occlusion. J Urol 166(1):281–284PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Dougherty TJ, Gomer CJ, Henderson BW et al (1998) Photodynamic therapy. J Natl Cancer Inst 90:889PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Kelly JF, Snell ME (1976) Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 115:150PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Windahl T, Andersson SO, Lofgren L (1990) Photodynamic therapy of localized prostatic cancer. Lancet 336:1139PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Du KL, Mick R, Busch T et al (2006) Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med 38:427–434PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Moore CM, Nathan TR, Lees WR et al (2006) Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 38:356–363PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Nathan TR, Whitelaw DE, Chang SC et al (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168:1427–1432PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Pinthus JH, Bogaards A, Weersink R et al (2006) Photodynamic therapy for urological malignancies: past to current approaches. J Urol 175:1201–1207PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Oleinick NL, Evans HH (1998) The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150:S146PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Korbelik M, Cecic I (1999) Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 137:91PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Hsi RA, Kapatkin A, Strandberg J et al (2001) Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res 7:651PubMedPubMedCentralGoogle Scholar
  105. 105.
    Lepor H (2008) Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol 10:254–261PubMedPubMedCentralGoogle Scholar
  106. 106.
    Mazor O, Brandis A, Plaks V et al (2005) WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake pharmacokinetics, biodistribution, and vascular targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 81:342–351PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Madar-Balakirski N, Tempel-Brami C, Kalchenko V et al (2010) Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (vtp) with tookad. PLoS ONE 5:e10282PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Chen Q, Huang Z, Luck D et al (2002) Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol 76(4):438–445PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Eggener SE, Coleman JA (2008) Focal treatment of prostate cancer with vascular-target photodynamic therapy. Sci World J 8:963–973CrossRefGoogle Scholar
  110. 110.
    Azzouzi AR, Barret E, Moore CM et al (2013) TOOKAD Soluble vascular targeted photodynamic (VTP) therapy: Determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112:766–774PubMedCrossRefGoogle Scholar
  111. 111.
    Moore CM, Azzouzi AR, Barret E et al (2015) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int 116:888–896PubMedCrossRefGoogle Scholar
  112. 112.
    Azzouzi AR, Vincendeau S, Barret E et al (2017) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18(2):181–191PubMedCrossRefGoogle Scholar
  113. 113.
    Lee EW, Wong D, Prikhodko SV et al (2012) Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol 23:107–113PubMedCrossRefGoogle Scholar
  114. 114.
    Miklavcic D, Mali B, Kos B, Heller R, Sersa G (2014) Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 13:29PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Davalos RV, Mir LM, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231PubMedCrossRefGoogle Scholar
  116. 116.
    Okino M, Mohri H (1987) Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 78:1319–1321PubMedGoogle Scholar
  117. 117.
    Mir LM, Orlowski S, Belehradek J Jr, Paoletti C (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27(1):68–72PubMedCrossRefGoogle Scholar
  118. 118.
    Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R (2007) Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat 6(4):313–320PubMedCrossRefGoogle Scholar
  119. 119.
    Thomson KR, Cheung W, Ellis SJ et al (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22(5):611–621PubMedCrossRefGoogle Scholar
  120. 120.
    Narayanan G, Hosein PJ, Arora G et al (2012) Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Intervent Radiol 23:1613–1621CrossRefGoogle Scholar
  121. 121.
    Neal RE, Milar JL, Kavnoudias H et al (2014) In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate 74(5):458–468PubMedCrossRefGoogle Scholar
  122. 122.
    Lee EW, Loh CT, Kee ST (2007) Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat 6:287–294PubMedCrossRefGoogle Scholar
  123. 123.
    Valerio M, Ahmed HU, Emberton M (2015) Focal therapy of prostate cancer using irreversible electroporation. Tech Vasc Interv Radiol 18(3):147–152PubMedCrossRefGoogle Scholar
  124. 124.
    Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B (2006) In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 53(7):1409–1415PubMedCrossRefGoogle Scholar
  125. 125.
    Valerio M, Dickinson L, Ali A et al (2017) Nanoknife electroporation ablation trial: A prospective development study investigating focal irreversible electroporation for localized prostate cancer. J Urol 197(3):647–654PubMedCrossRefGoogle Scholar
  126. 126.
    Ting F, Tran M, Bohm M et al (2016) Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 19:46–52PubMedCrossRefGoogle Scholar
  127. 127.
    Valerio M, Stricker PD, Ahmed HU et al (2014) Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 17:343–347PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Scheltema MJ, van den Bos W, de Bruin DM, et al Focal versus extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/27150293 [Accessed 15 March 2017]
  129. 129.
    Jain S, Hirst DG, O’Sullivan JM (1010) Gold nanoparticles as novel agents for cancer therapy. Br J Radiol 2012(85):101–113Google Scholar
  130. 130.
    Alric C, Taleb J, Duc GL et al (2008) Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc 130(18):5908–5915PubMedCrossRefGoogle Scholar
  131. 131.
    Brown SD, Nativo P, Smith JA et al (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132(13):4678–4684PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Cheng YC, Samia A, Meyers JD et al (2008) Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 130(32):10643–10647PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    O’Neal DP, Hirsch LR, Halas NJ et al (2004) Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 209(2):171–176PubMedCrossRefGoogle Scholar
  134. 134.
    Bernardi RJ, Lowery AR, Thompson PA, et al (2008) Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol 86(2):1 65–172Google Scholar
  135. 135.
    Popovtzer A, Mizrachi A, Motiei M et al (2016) Actively targeted gold nanoparticles as novel radiosensitizer agents: an in vivo head and neck cancer model. Nanoscale 8:2678–2685PubMedCrossRefGoogle Scholar
  136. 136.
    Stern JM, Stanfield J, Kabbani W et al (2008) Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol 179(2):748–753PubMedCrossRefGoogle Scholar
  137. 137.
    Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3(3):319–328PubMedCrossRefGoogle Scholar
  138. 138.
    Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74(1–3):47–61PubMedCrossRefGoogle Scholar
  139. 139.
    Ishida O, Maruyama K, Sasaki K et al (1999) Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 190(1):49–56PubMedCrossRefGoogle Scholar
  140. 140.
    Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207PubMedCrossRefGoogle Scholar
  141. 141.
    James WD, Hirsch LR, West JL et al (2007) Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice. J Radioanal Nuclear Chem 271(2):455–459CrossRefGoogle Scholar
  142. 142.
    Schwartz JA, Price RE, Gill-Sharp KL et al (2011) Selective nanoparticle-directed ablation of the canine prostate. Lasers Surg Med 43:213–220PubMedCrossRefGoogle Scholar
  143. 143.
    Oldenburg SJ, Averitt RD (1998) Westcott SL, etc. Nanoengineering of optical resonances. Chem Phys Lett 288:243–247CrossRefGoogle Scholar
  144. 144.
    Oldenburg SJ, Jackson JB, Westcott SL et al (1999) Infrared extinction properties of gold nanoshells. Appl Phys Lett 75(19):2897–2899CrossRefGoogle Scholar
  145. 145.
    Gad SC, Sharp KL, Montgomery C et al (2012) Evaluation of the toxicity of intravenous delivery of auroshell particles (gold-silica nanoshells). Int J Toxicol 31(6):584–594PubMedCrossRefGoogle Scholar
  146. 146.
    Stern JM, Solomonov V, Sazykina E et al (2016) Initial evaluation of the safety of nanoshell-directed photothermal therapy in the treatment of prostate disease. Int J Toxicol 35(1):38–46PubMedCrossRefGoogle Scholar
  147. 147.
    Winoker JS, Shukla PA, Carrick MA, et al (2017) Gold nano-particle directed focal laser ablation for prostate tumors using US and MR fusion technology. Poster session presented at: American Urological Association Annual Meeting, Boston, MA, pp 12–16Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jared S. Winoker
    • 1
  • Harry Anastos
    • 1
  • Ardeshir R. Rastinehad
    • 1
    • 2
  1. 1.Department of UrologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of RadiologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations